Follicular Lymphoma International Prognostic Index.
Reads0
Chats0
TLDR
The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.Abstract:
Although numerous treatment approaches are proposed for patients with follicular lymphoma, criteria to help in choosing a treatment for a given patient and for comparing trial results are lacking. Several retrospective studies have analyzed prognostic factors, but their conclusions rely on limited numbers of patients treated during long periods, and their results are discordant. The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide. Five factors are used (age, Ann Arbor stage, number of nodal sites, serum lactate dehydrogenase level, and hemoglobin level) to build a three-category index. This index, together with new biologic markers such as gene profiling and proteomics, could help provide an optimal treatment option for patients with follicular lymphoma.read more
Citations
More filters
Journal ArticleDOI
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson,Richard I. Fisher,Sally F. Barrington,Franco Cavalli,Lawrence H. Schwartz,Emanuele Zucca,T. Andrew Lister +6 more
TL;DR: Recommendations to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma and non-Hodgkin lymphomas and enhance the ability to compare outcomes of clinical trials are made.
Journal ArticleDOI
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave,George E. Wright,Bruce K. Tan,Andreas Rosenwald,Andreas Rosenwald,Randy D. Gascoyne,Wing C. Chan,Richard I. Fisher,Rita M. Braziel,Lisa M. Rimsza,Thomas M. Grogan,Thomas P. Miller,Michael LeBlanc,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Joseph M. Connors,Peter M. Lansdorp,Qin Ouyang,T. Andrew Lister,Andrew Davies,Andrew J. Norton,H. Konrad Muller-Hermelink,German Ott,Elias Campo,Emilio Montserrat,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Liming Yang,John Powell,Hong Zhao,Neta Goldschmidt,Michael Chiorazzi,Louis M. Staudt +40 more
TL;DR: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.
Journal ArticleDOI
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas M. Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt +22 more
TL;DR: Adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects.
Journal ArticleDOI
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington,N. George Mikhaeel,Lale Kostakoglu,Michel Meignan,Martin Hutchings,Stefan P. Müeller,Lawrence H. Schwartz,Emanuele Zucca,Richard I. Fisher,Judith Trotman,Otto S. Hoekstra,Rodney J. Hicks,Michael O'Doherty,Roland Hustinx,Alberto Biggi,Bruce D. Cheson +15 more
TL;DR: This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Journal ArticleDOI
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel,Norbert Niederle,Georg Maschmeyer,G.-Andre Banat,Ulrich von Grünhagen,Christoph Losem,Dorothea Kofahl-Krause,Gerhard Heil,Manfred Welslau,Christina Balser,Ulrich Kaiser,Eckhart Weidmann,Heinz Dürk,Harald Ballo,Martina Stauch,Fritz Roller,Juergen Barth,Dieter Hoelzer,Axel Hinke,Wolfram Brugger +19 more
TL;DR: In patients with previously untreated indolent lymphoma, bendamustine plus rituximab can be considered as a preferred first-line treatment approach to R-CHOP because of increased progression-free survival and fewer toxic effects.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors
TL;DR: An easily interpretable index of predictive discrimination as well as methods for assessing calibration of predicted survival probabilities are discussed, applicable to all regression models, but are particularly needed for binary, ordinal, and time-to-event outcomes.
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin,Antonio J. Grillo-Lopez,Brian K. Link,Ronald Levy,Myron S. Czuczman,Michael E. Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vinay K. Jain,A D Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
TL;DR: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Journal ArticleDOI
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Lindsay M. Morton,Sophia S. Wang,Sophia S. Wang,Susan S. Devesa,Susan S. Devesa,Patricia Hartge,Patricia Hartge,Dennis D. Weisenburger,Dennis D. Weisenburger,Martha S. Linet,Martha S. Linet +10 more
TL;DR: Striking differences in incidence patterns by histologic subtype strongly suggest that there is etiologic heterogeneity among lymphoid neoplasms and support the pursuit of epidemiologic analysis by subtype.
Related Papers (5)
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico,Monica Bellei,Luigi Marcheselli,Stefano Luminari,Armando López-Guillermo,Umberto Vitolo,Barbara Pro,Stefano Pileri,Alessandro Pulsoni,Pierre Soubeyran,Sergio Cortelazzo,Giovanni Martinelli,Maurizio Martelli,Luigi Rigacci,Luca Arcaini,Francesco Di Raimondo,Francesco Merli,Elena Sabattini,Peter McLaughlin,Philippe Solal-Celigny +19 more